BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11395133)

  • 1. Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein.
    Meng WS; Butterfield LH; Ribas A; Heller JB; Dissette VB; Glaspy JA; McBride WH; Economou JS
    Mol Immunol; 2000 Nov; 37(16):943-50. PubMed ID: 11395133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein.
    Butterfield LH; Koh A; Meng W; Vollmer CM; Ribas A; Dissette V; Lee E; Glaspy JA; McBride WH; Economou JS
    Cancer Res; 1999 Jul; 59(13):3134-42. PubMed ID: 10397256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination.
    Meng WS; Butterfield LH; Ribas A; Dissette VB; Heller JB; Miranda GA; Glaspy JA; McBride WH; Economou JS
    Cancer Res; 2001 Dec; 61(24):8782-6. PubMed ID: 11751399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.
    Butterfield LH; Meng WS; Koh A; Vollmer CM; Ribas A; Dissette VB; Faull K; Glaspy JA; McBride WH; Economou JS
    J Immunol; 2001 Apr; 166(8):5300-8. PubMed ID: 11290817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer.
    Liu Y; Daley S; Evdokimova VN; Zdobinski DD; Potter DM; Butterfield LH
    J Immunol; 2006 Jul; 177(1):712-21. PubMed ID: 16785570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy.
    Zhu W; Peng Y; Wang L; Hong Y; Jiang X; Li Q; Liu H; Huang L; Wu J; Celis E; Merchen T; Kruse E; He Y
    Hepatology; 2018 Aug; 68(2):574-589. PubMed ID: 29443377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of an HLA-A*24:02-restricted α-fetoprotein signal peptide-derived antigen and its specific T-cell receptor for T-cell immunotherapy.
    Li Z; Gong H; Liu Q; Wu W; Cheng J; Mei Y; Chen Y; Zheng H; Yu X; Zhong S; Li Y
    Immunology; 2020 Apr; 159(4):384-392. PubMed ID: 31849039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.
    Butterfield LH; Ribas A; Dissette VB; Lee Y; Yang JQ; De la Rocha P; Duran SD; Hernandez J; Seja E; Potter DM; McBride WH; Finn R; Glaspy JA; Economou JS
    Clin Cancer Res; 2006 May; 12(9):2817-25. PubMed ID: 16675576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit.
    Luo X; Cui H; Cai L; Zhu W; Yang WC; Patrick M; Zhu S; Huang J; Yao X; Yao Y; He Y; Ji Y
    Front Immunol; 2020; 11():623. PubMed ID: 32425926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.
    Butterfield LH; Ribas A; Meng WS; Dissette VB; Amarnani S; Vu HT; Seja E; Todd K; Glaspy JA; McBride WH; Economou JS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5902-8. PubMed ID: 14676113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma.
    Mizukoshi E; Nakamoto Y; Tsuji H; Yamashita T; Kaneko S
    Int J Cancer; 2006 Mar; 118(5):1194-204. PubMed ID: 16152611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
    Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
    Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
    Terasawa H; Tsang KY; Gulley J; Arlen P; Schlom J
    Clin Cancer Res; 2002 Jan; 8(1):41-53. PubMed ID: 11801539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer.
    Liu H; Xu Y; Xiang J; Long L; Green S; Yang Z; Zimdahl B; Lu J; Cheng N; Horan LH; Liu B; Yan S; Wang P; Diaz J; Jin L; Nakano Y; Morales JF; Zhang P; Liu LX; Staley BK; Priceman SJ; Brown CE; Forman SJ; Chan VW; Liu C
    Clin Cancer Res; 2017 Jan; 23(2):478-488. PubMed ID: 27535982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients.
    Alisa A; Ives A; Pathan AA; Navarrete CV; Williams R; Bertoletti A; Behboudi S
    Clin Cancer Res; 2005 Sep; 11(18):6686-94. PubMed ID: 16166448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
    Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer.
    Docta RY; Ferronha T; Sanderson JP; Weissensteiner T; Pope GR; Bennett AD; Pumphrey NJ; Ferjentsik Z; Quinn LL; Wiedermann GE; Anderson VE; Saini M; Maroto M; Norry E; Gerry AB
    Hepatology; 2019 May; 69(5):2061-2075. PubMed ID: 30561769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel α-fetoprotein-derived helper T-lymphocyte epitope with strong immunogenicity in patients with hepatocellular carcinoma.
    Tamai T; Mizukoshi E; Kumagai M; Terashima T; Iida N; Kitahara M; Shimakami T; Kitamura K; Arai K; Yamashita T; Sakai Y; Yamashita T; Honda M; Fushimi K; Kaneko S
    Sci Rep; 2020 Mar; 10(1):4021. PubMed ID: 32132566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization.
    Ayaru L; Pereira SP; Alisa A; Pathan AA; Williams R; Davidson B; Burroughs AK; Meyer T; Behboudi S
    J Immunol; 2007 Feb; 178(3):1914-22. PubMed ID: 17237442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.